Multiple Sclerosis Clinical Trial
HFP (High-Fiber Supplement) in MS (Multiple Sclerosis)
It has been suggested that dysbiosis of gut commensal bacteria increases the risk of autoimmune diseases including MS. However, there is no viable intervention available to correct dysbiosis. Since high-fiber supplement can promote the growth of healthy bacteria in the gut, the investigators propose to examine the effect of specially designed high-fiber supplement on the growth of short-chain fatty acid-producing gut bacteria and development of regulatory immune cells.
Although dysbiosis is an alteration of microbial composition, enteric bacteria involved in gut dysbiosis of MS are different in ethnic groups due to difference in genetics, diet, and environmental exposures. Therefore, it is important to determine the intestinal bacterial composition involved in the MS dysbiosis in each ethnicity and geographical location. Additionally, it is necessary to find a non-invasive biomarker for gut dysbiosis-mediated CNS autoimmunity in MS. Since the investigators found that fecal Lipocalin 2 (Lcn-2) is a biomarker of gut dysbiosis-mediated CNS autoimmunity in MS animal models, the investigators will examine the association of fecal Lcn-2 levels with disease activation in MS.
Our collaborator, Dr. Liping Zhao, developed a high fiber supplement (HFS), NBT-NM108. His recent study suggests an association between intake of NBT-NM108 and reduced gut dysbiosis and increased abundance of short chain fatty acid (SCFA)-producing gut bacteria. Since reports suggest that Relapsing Remitting Multiple Sclerosis (RRMS) may be associated with gut dysbiosis and decreased production of SCFAs, we will investigate the effect of NBT-NM108 on RRMS-associated gut dysbiosis. 50 RRMS patients will be enrolled. The first group (Group A) of RRMS patients (n=25) will receive NBT-NM108 for 12 weeks (High-fiber supplement group). The second group of RRMS patients (Group B) (n=25) will not consume any high fiber supplement. We will investigate the effect of NBT-NM108 on gut microbiota and immune parameters involved in MS.
We will also investigate the association between intestinal inflammation and relapse. The blood and fecal samples will be collected at the time of relapse and remission, and fecal Lipocalin 2 levels, an intestinal inflammation biomarker, will be examined.
Patients with first demyelinating event who meet the McDonald criteria for definite MS or established relapsing remitting MS patients.
We will recruit Caucasian due to reports suggesting higher incidence of MS in Caucasian. Also, western diet which is common among Caucasian can promote MS.
MS patients treated with either Glatiramer acetate or Fingolimod for at least 6 months prior to enrollment.
Primary or secondary progressive MS.
Patients with autoimmune comorbidities.
Having received prior chemotherapy.
Having received Dimethylfumarate (DMF).
Antibiotic use within last 6 months.
Probiotic use within 2 months.
Self-reported allergy or intolerance to any ingredients in the fiber supplement
Self-reported or diagnosed gastrointestinal symptoms, disorders or adenomas
Active or history of malignant tumors
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New Brunswick New Jersey, 08901, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.